Unveiling Seeking Alpha’s Top 10 Stocks for the Remainder of 2025

Alright, let’s talk stocks! If you’re like me, you’re always on the lookout for what’s next, especially when it comes to investments that could really make a difference. We’re heading into the latter half of 2025, and the market is buzzing with possibilities. I’ve been digging around, looking at what the smart folks at Seeking Alpha are highlighting, and I’ve put together a list of the top 10 stocks that seem to have a lot of potential. This isn’t just about big names; it’s about companies doing interesting things that could pay off. So, if you’re curious about where some of the best opportunities might be, keep reading for my take on Seeking Alpha’s top 10 stocks.

Key Takeaways

• Biotech and AI are big players for 2025, with companies like Unity Biotechnology and Isomorphic Labs showing promise in new drug discovery.
• Established pharmaceutical giants such as Eli Lilly and Novartis are still strong contenders, adapting to new tech and research areas.
• Companies using artificial intelligence, like DeepMind and AlphaFold, are changing how research and development happen, especially in medicine.
• Some companies, like Nasdaq, are important for the market itself, offering stability and growth through their core business operations.
• The seeking alpha top 10 stocks list for the rest of 2025 heavily features firms at the cutting edge of science and technology, pointing to innovation as a key driver for future returns.

1. Unity Biotechnology

Unity Biotechnology is definitely one of the more interesting companies out there, focusing on UBX stock quotes and developing treatments to combat aging. They’re trying to tackle diseases linked to getting older by getting rid of or changing senescent cells – those old cells that build up and cause problems. Their main focus right now is on eye and brain diseases.

Unity’s approach centers around senolytics, drugs designed to clear out these harmful senescent cells. It’s a pretty novel idea, and if it works, it could really change how we deal with age-related illnesses. However, it’s worth remembering that biotech, especially in the longevity field, is a risky game. Here are a few things to keep in mind:

• Drug development takes a long time and costs a lot of money. There are no guarantees of success.
• Getting approval from regulators like the FDA is tough because aging isn’t officially recognized as a disease. Companies have to target specific illnesses, which makes things more complicated.
• Clinical trials can fail, and that can lead to big losses for investors. We saw that happen with Unity’s earlier work on osteoarthritis.

Despite the risks, the potential rewards are huge. If Unity can successfully develop and market its senolytic therapies, it could be a game-changer in the fight against aging. It’s definitely a company to watch, but investors should be aware of the challenges and uncertainties involved.

2. Calico

Calico, another Alphabet subsidiary, is focused on understanding the biology of aging. Their goal? To develop interventions that help people live longer, healthier lives. It’s a pretty ambitious project, and it’s interesting to see how they’re approaching it.

Calico’s lead candidate, fosigotifator, targets eIF2B, which is important for protein synthesis. This is a key regulator of the Integrated Stress Response (ISR). They’re currently running a Phase 1b/II trial with AbbVie to evaluate fosigotifator for Vanishing White Matter (VWM) disease, a rare genetic brain disorder. This is the first time an eIF2B activator is being tested in VWM patients, so it’s a pretty big deal. They’re also looking at it for amyotrophic lateral sclerosis (ALS) in two ongoing studies, although there was a report of a "fail in ALS" earlier this year, but the details are scarce. You can follow Alphabet’s growth opportunities to stay updated on their progress.

Here’s a quick rundown of what to watch for in the second half of 2025:

• Early-stage data from the CDK7 inhibitor program (acquired from Exscientia) and REC-4881 (FAP).
• Progress in their oncology and rare disease pipeline.
• Milestones from existing biopharma collaborations.
• Advancements using Google Cloud’s generative AI tools to improve their discovery platform.

3. Isomorphic Labs

Isomorphic Labs, another Alphabet company, is making waves in the drug discovery space. They’re all about using AI to design new drugs, and they’re not just talking the talk. They’ve got some serious partnerships and funding to back them up. It’s pretty cool to see how AI is changing the game in medicine.

Isomorphic Labs is working with big names like Eli Lilly and Novartis, focusing on areas like oncology and cardiovascular diseases. They’re using their AI platform to speed up the process of finding new drug candidates. Plus, they secured $600 million in funding in Q1 2025, which shows that investors are taking them seriously. It’s a good sign for their future and the potential of AI in drug development.

Here’s a quick rundown of what they’re up to:

• AI-Designed Drugs: Aiming to get their first AI-designed drug into clinical trials by the end of 2025.
• Collaborations: Partnering with Eli Lilly and Novartis for oncology and cardiovascular research.
• Funding: Secured $600 million in Q1 2025 to advance their pipeline and AI drug design engine.

Alphabet’s Q1 2025 earnings, reported in April, showed EPS of $2.81, beating expectations. However, Q2 2025 EPS is projected to be lower, around $2.16, due to increased investment in AI. Still, the stock has shown positive momentum, and Tickeron’s Valuation Rating considers it slightly undervalued. Isomorphic Labs is definitely one to watch as they push the boundaries of AI in drug discovery. DeepMind released AlphaFold 3, this AI model predicts the structure and interactions of proteins, DNA, RNA, and small molecules, significantly enhancing drug target identification and therapeutic design.

4. DeepMind

DeepMind, an Alphabet subsidiary, is making waves in the longevity and drug discovery fields. Their focus is on applying artificial intelligence to accelerate the process of finding and designing new drugs. They’re not just about speed; they’re aiming for a more personalized approach to healthspan extension.

DeepMind’s AlphaFold 3, released not too long ago, is a game-changer. It predicts the structure and interactions of proteins, DNA, RNA, and small molecules. This significantly improves how we identify drug targets and design therapies. It’s like having a super-powered microscope that can see the tiniest details of how molecules interact. This is a big deal for best stocks to invest in 2025.

Google introduced an AI co-scientist powered by Gemini 2 in March 2025. This system can generate hypotheses, design experiments, and analyze complex datasets. It’s already identified a new gene transfer mechanism linked to antimicrobial resistance and potential drug candidates for liver fibrosis, which was validated by Stanford. Pretty impressive, right?

5. Eli Lilly

Eli Lilly is a major player in the pharmaceutical world, and while they aren’t specifically a longevity company, their work has serious implications for how long and how well we live. Think metabolic diseases and their AI-driven drug discovery efforts. They’re making moves that could really impact healthspan.

Eli Lilly’s stock has seen a significant increase of 376.40% over the last five years, showing strong investor confidence stock increase.

Here’s a quick rundown:

• GLP-1 Receptor Agonists (like Zepbound): Zepbound is a big deal. It’s approved for obesity and even helps with sleep apnea in adults who are obese. Since obesity is linked to a bunch of age-related problems, managing weight with drugs like Zepbound can really improve health. They’re also working on making it more accessible with new doses and programs like LillyDirect.
• AI Drug Discovery: They’re teaming up with Isomorphic Labs (part of Alphabet) to use AI to find new drugs. Isomorphic is aiming to have its first AI-designed drug ready for clinical trials by the end of 2025. This AI collaboration could lead to some major breakthroughs.
• Oncology Research: Lilly is also working hard on cancer research, which is obviously a huge age-related issue. They presented some interesting preclinical data at AACR 2025, targeting things like SMARCA2 and certain KRAS mutations.

They’re also involved in events like BIO-Europe Spring 2025 and ECO 2025 to talk about their work. Keep an eye on Lilly; they’re definitely one to watch in the longevity space.

6. Novartis

Novartis is a major player in the pharmaceutical world, and while they aren’t exclusively focused on longevity, their work in areas like heart health, brain science, and cancer research makes them relevant to the healthspan conversation. They’re also exploring cutting-edge tech like AI, which could speed up the discovery of new treatments for age-related diseases. It’s interesting to see how established companies are adapting to new research areas.

Here’s a quick rundown of what makes Novartis interesting in this space:

• They’re using AI in drug discovery, partnering with companies like Isomorphic Labs to find new treatments for complex conditions. This could lead to breakthroughs in areas like oncology and cardiovascular disease.
• Novartis is active in therapeutic areas that are highly relevant to aging, including cardiovascular, renal, metabolic diseases, immunology, neuroscience, and oncology. Their broad focus means they’re tackling many of the diseases that affect us as we age.
• They’re listed among key companies in the senolytics and anti-aging pharmaceuticals market, suggesting they’re exploring ways to clear out old, damaged cells that contribute to aging. It’s not clear what specific programs they have, but it’s something to watch.

Novartis is also involved in gene therapy, which has potential applications in longevity. They’re profiled as a key company in the U.S. Cell and Gene Therapy CDMO market and U.S. Gene Therapy market, indicating capabilities and involvement in this advanced therapeutic modality.

Looking ahead to the rest of 2025, here are a few things to keep an eye on:

• Progress from the Isomorphic Labs collaboration. If they can identify promising drug candidates using AI, it could be a big step forward.
• Advancements in their core therapeutic areas (cardiovascular, neuroscience, oncology) that could impact healthspan. Even if they’re not directly targeting aging, treatments for these diseases can improve quality of life and extend lifespan.

It’s worth noting that Novartis has a fund that supports PhD student research projects in decision science related to health policy, including projects on Alzheimer’s Disease clinical trials. While this isn’t direct drug development, it shows an interest in understanding and addressing major age-related conditions.

7. BenevolentAI

Okay, so here’s the deal with BenevolentAI. It’s a bit of a complicated situation, honestly. They were doing some pretty interesting stuff with AI and drug discovery, but things have changed quite a bit recently.

• BenevolentAI merged into Osaka Holdings S.à r.l. on March 12, 2025, and was delisted from Euronext Amsterdam.

Basically, the original company doesn’t exist anymore. It’s now part of a privately held entity. What does this mean for investors? Well, you can’t directly invest in the old BenevolentAI anymore. The technology and assets are still around, but they’re under new management. It’s a good reminder that the biotech world can be pretty unpredictable, with mergers and acquisitions changing the landscape all the time. It’s important to keep an eye on these things if you’re looking to buy OpenAI stock or any other stock for that matter.

Here’s a quick rundown of what happened:

• March 2024: Announced a strategic review and cost reductions.
• March 12, 2025: Merged into Osaka Holdings.
• March 13, 2025: Shares delisted from Euronext Amsterdam.

It’s a bummer for those who were following BenevolentAI, but that’s how it goes sometimes. Keep an eye out for what the new BenevolentAI does under Osaka Holdings; maybe they’ll still make waves in the AI drug discovery space. They were using their AI platform to identify new drug candidates and repurpose existing drugs, so it will be interesting to see if that continues. They had Kenneth Mulvany as Executive Chairman, but it’s unclear who is in charge now. We’ll have to wait and see what happens next. They were also working on a streamlined oncology and rare disease pipeline, so hopefully, that work continues. They were also using Google Cloud’s generative AI tools to enhance their discovery platform.

8. Tickeron

Tickeron is an interesting player in the stock analysis space, especially with its focus on AI. It’s basically a platform where you can find trading bots and other AI-driven tools to help with your investment decisions. I’ve been playing around with it a bit, and here’s my take.

One of the things that stands out is the daily buy/sell signals you get with even the basic membership. It’s like having a little AI assistant whispering in your ear, telling you what to do. Of course, you shouldn’t blindly follow these signals, but they can be a good starting point for your own research. It’s worth checking out their stock polls too, to see what the community thinks.

Here’s a quick rundown of what I like and don’t like about Tickeron:

• Pros:
  • AI-driven analysis can help identify potential opportunities.
  • Daily buy/sell signals provide a starting point for research.
  • A marketplace for various trading bots allows for customization.
• Cons:
  • AI is not perfect, and signals should be used with caution.
  • The platform can be a bit overwhelming for beginners.
  • The cost of advanced features can add up quickly.

Overall, Tickeron seems like a useful tool for investors who are comfortable with AI and want to add another layer of analysis to their decision-making process. Just remember to do your own homework and not rely solely on the AI & Big Data Forecast.

9. Nasdaq

Nasdaq is more than just a stock exchange; it’s a technology company in its own right. It’s interesting to consider Nasdaq itself as a potential investment, especially given its role in facilitating the growth of other innovative companies. Let’s take a closer look.

Nasdaq’s performance is closely tied to the overall health of the tech sector and the broader economy. When tech companies thrive, Nasdaq tends to do well. It’s a bit of a bellwether, really. But it also faces challenges, like increased competition from other exchanges and the ever-present threat of market volatility.

Nasdaq’s diverse revenue streams, including market services, information services, and technology solutions, provide a degree of stability. It’s not just about trading; they’re also heavily involved in data analytics and providing tech solutions to other businesses. This diversification is key to their long-term success.

Here are a few things to keep in mind when considering Nasdaq as an investment:

• Market Trends: Keep an eye on the overall market sentiment, especially regarding tech stocks. A rising tide lifts all boats, and a strong tech sector generally benefits Nasdaq.
• Competition: The exchange landscape is becoming increasingly competitive. New players and alternative trading systems are constantly emerging, so it’s important to assess how Nasdaq is adapting.
• Innovation: Nasdaq needs to continue innovating and expanding its services to stay ahead of the curve. This includes investing in new technologies and exploring new markets.

It’s also worth noting that Nasdaq provides USA Stock Forecast and other stock forecasts. This could be a valuable tool for investors looking to make informed decisions. They also offer various indexes, including the MSCI USA Index, which can be used to track market performance.

Ultimately, investing in Nasdaq is a bet on the continued growth and innovation of the technology sector. It’s a solid choice for investors looking for exposure to the market as a whole, but it’s important to do your homework and understand the risks involved.

10. AlphaFold

Alphabet Inc., through its DeepMind subsidiary, continues to push the boundaries of AI in drug discovery with AlphaFold. It’s pretty amazing, honestly. While Alphabet is a tech giant, its investments in longevity research are noteworthy, especially through Calico Life Sciences and DeepMind/Isomorphic Labs. These ventures are all about understanding aging and finding ways to combat age-related diseases.

AlphaFold 3, released not too long ago, can predict the structure and interactions of proteins, DNA, RNA, and even small molecules. This is a game-changer for identifying drug targets and designing new therapies. Google also introduced an AI co-scientist powered by Gemini 2, which can generate hypotheses, design experiments, and analyze complex datasets. It’s already found a new gene transfer mechanism linked to antimicrobial resistance and potential drug candidates for liver fibrosis. It’s like having a super-smart research assistant that never sleeps!

Here’s a quick rundown of what to watch for with Alphabet’s longevity efforts:

• Progress in Calico’s fosigotifator trials for VWM and ALS. It’s a long road, but any positive news would be huge.
• Isomorphic Labs aiming to get its first AI-designed drug into clinical trials by the end of the year. That’s a big milestone.
• Further breakthroughs from DeepMind’s AlphaFold and AI co-scientist platforms impacting drug discovery. The more they learn, the better.
• Updates from Isomorphic Labs’ collaborations with Eli Lilly and Novartis. Partnerships are key in this field.

Alphabet’s investment calls for 2025 are definitely something to keep an eye on, especially if you’re interested in the intersection of tech and healthcare. It’s a long-term play, but the potential is massive.

Wrapping It Up: What to Remember for 2025

So, there you have it. Picking stocks for the rest of 2025 isn’t an exact science, and nobody has a crystal ball. We looked at some of Seeking Alpha’s top picks, and they seem pretty solid. But, you know, things can change fast. The market can be a bit wild sometimes. The main thing is to do your own homework. Don’t just jump in because someone else said so. Think about what you’re comfortable with, and keep an eye on the news. Good luck out there!